The Nanomedicine Lab is currently involved in the following collaborative projects:
Engineering Responsive Nanomaterials for Pulsatile Neural Regeneration
The Nanomedicine Lab in collaboration with the UCL Institute of Neurology was awarded by the Engineering and Physical Sciences Research Council (EPSRC) grant to address the development and functionality of electroresponsive hydrogel scaffolds capable of releasing therapeutic agents in response to an externally applied electrical field. The aim is to translate such innovative delivery systems to a therapeutic tool against neurodegenerative diseases.
UK-KOREA Nanomedicine and Molecular Imaging (GPF)
A project awarded as a GLOBAL PARTNERSHIPS FUND (GPF) in the context of the Life Sciences Focal Point Programme, managed by the Department of Business Innovation and Skills (BIS) of the British Embassy in Seoul, South Korea. BIS as part of the Science and Innovation Network (SIN), a key delivery mechanism for strengthening the UK’s science and innovation capacity through international collaboration in science and innovation, has awarded this project to the Nanomedicine Lab at UCL and the Department of Nuclear Medicine, Seoul National University Medical School aiming to reinforse collaboration and form a UK-KOREA network for Nanomedicine.
Nanocapsules for Targeted Delivery of Radioactivity (FP7 – Marie Curie – ITN)
The RADDEL Project is in collaboration with:
Consejo Superior de Investigaciones Científicas (CSIC), Spain
King’s College London, UK
University of Trieste, Italy
Catalan Institute of Nanotechnology (ICN), Spain
University of Ioannina, Greece
J. Heyrovsky Institute of Physical Chemistry, Czech Republic
CIS Bio International, France
Management of Resistance to Tyrosine Kinase Inhibitors with Advanced Nanosystems (FP7 – Marie Curie – IAPP)
The NANORESISTANCE Project is in collaboration with:
Image-Controlled Ultrasound-Induced Drug Delivery (FP7 – Health – IP)
The SONODRUGS Project is in collaboration with:
Philips Electronics Nederland B.V, The Netherlands
Philips Technologies GmbH Forschungslaboratorien, Germany
Lipoid GmbH, Germany
University of Cyprus, Cyprus
Ghent University, Belgium
University of Helsinki, Finland
Technische Universiteit Eindhoven, The Netherlands
Université François-Rabelais de Tours, France
Bordeaux Segalen University, France
Philips Medical Systems, Finland
University of Udine, Italy
Erasmus University Medical Center Rotterdam, The Netherlands
Westfälische Wilhelms-Universität Münster, Germany
COST Action TD1004: Theragnostics Imaging and Therapy
An Action to Develop Novel Nanosized Systems for Imaging-Guided Drug Delivery. Action TD1004 brings together major European research groups working on the development of novel combined diagnostic/therapeutic agents (theragnostic agents) from 19 European countries. The main objective of the Action is to demonstrate the potential of image-guided therapies in the treatment of diseases with high social impact. The Nanomedicine Lab is the UK representative to the Action Management Committee.
The NANOCHANNELS project is a unique public experiment of democratic dialogue in action about the new industrial revolution that could change the face of medicine, energy production and water purification, electronics, materials and security. The Nanomedicine Lab and Prof. Kostarelos are on the Advisory Board of the project in collaboration with:
The Nanomedicine Lab has successfully completed the following collaborative projects:
Monoclonal Antibody-targeted Carbon Nanotubes against Cancer (FP7 – Health – STREP)
The ANTICARB Project is in collaboration with:
Grand Challenge in the application of Nanotechnology to Healthcare
The Nanomedicine Lab in collaboration with School of Engineering at Swansea University has been awarded a major grant by the Engineering and Physical Sciences Research Council (EPSRC) to address a Grand Challenge in the application of Nanotechnology to Healthcare.
The project is titled: ‘Point of care nanotechnology for early blood clot detection and characterisation in disease screening, theranostic and self monitoring applications‘ and was ranked first in the UK – in the EPSRC’s priority order for funding.